HORMONE RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo for advanced breast cancer shows early safety
Disease control CompletedThis early-phase study tested a combination of two drugs—capecitabine (a chemotherapy pill) and cemiplimab (an immunotherapy)—in 13 people with hormone receptor-positive breast cancer that had spread. The main goal was to find the safest dose and see if the combination helped shr…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New hope in hormone therapy battle against advanced breast cancer
Disease control CompletedThis study tested two hormone-blocking drugs, fulvestrant and anastrozole, in 462 postmenopausal women with advanced breast cancer that is fueled by hormones. The goal was to see which drug better delays cancer growth. Participants had not received hormone therapy before. The res…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Real-world study checks how breast cancer patients cope with hormone-blocking shots
Knowledge-focused CompletedThis study followed 562 premenopausal women with hormone receptor-positive breast cancer after surgery. Researchers wanted to understand their quality of life and how well they stuck to treatment with GnRHa, a drug that temporarily stops the ovaries from making estrogen. The goal…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated May 26, 2026 04:12 UTC